Ad5-nCoV vaccine

Also Known As:

2019-nCoV vaccine Ad5-nCoV; Ad5-nCoV 2019-nCoV vaccine; Ad5-nCoV COVID-19 vaccine; COVID-19 vaccine Ad5-nCoV; Convidicea; Pakvac; Recombinant Novel Coronavirus Vaccine Ad5-nCoV; hAdOx1 nCoV-19; recombinant novel coronavirus vaccine adenoviral vector5

Networked: 6 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1947
- Biological Products
  - Vaccines: 128365
    - Viral Vaccines: 473
      - COVID-19 Vaccines: 8432
        Ad5-nCoV vaccine: 6

Experts

1.	Hernández-Bello, Jorge: 3 articles (01/2024 - 09/2021)
2.	Díaz-Pérez, Saúl Alberto: 2 articles (12/2022 - 09/2021)
3.	Machado-Sulbarán, Andrea Carolina: 2 articles (12/2022 - 09/2021)
4.	Morales-Núñez, José Javier: 2 articles (12/2022 - 09/2021)
5.	Muñoz-Valle, José Francisco: 2 articles (12/2022 - 09/2021)
6.	Torres-Hernández, Paola Carolina: 2 articles (12/2022 - 09/2021)
7.	Bach, Horacio: 1 article (01/2024)
8.	Díaz-Pérez, Saul A: 1 article (01/2024)
9.	Hernández-Gutiérrez, Rodolfo: 1 article (01/2024)
10.	Lorenzo-Leal, Ana C: 1 article (01/2024)

Related Diseases

1.	Asymptomatic Infections 01/01/2023 - "Successful clearance of persistent SARS-CoV-2 asymptomatic infection following a single dose of Ad5-nCoV vaccine."
2.	COVID-19 01/01/2024 - "During the COVID-19 pandemic, the Ad5-nCoV vaccine was applied to the Mexican population before the WHO approved it. " 01/01/2023 - "Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19." 12/01/2022 - "In individuals without prior COVID-19, the Ad5-nCoV vaccine generated lower NAbs against SARS-CoV-2 than those induced by two doses of the BTN162b2 (Ad5-nCoV 72.10 [55.6-93.4] vs. BTN162b2 98.41 [98.16-98.56], p < 0.0001). " 02/10/2022 - "The patient received a single dose of Ad5-nCoV vaccine (Convidecia™, CanSino Biologics Inc.) one month before developing COVID-19 symptoms. " 12/01/2022 - "In conclusion, the mRNA vaccine (BTN162b2) had a remarkable better ability to produce NAbs and lower reactogenicity than the other platforms, whereas the Ad5-nCov vaccine induced the lowest NAbs response in individuals without a history of COVID-19; therefore, we suggest that a booster could benefit these individuals."

Related Drugs and Biologics

1.	Neutralizing Antibodies
2.	mRNA Vaccines